MyoKardia, Inc. (MYOK) Stock Is Rising Now

February 18, 2018 - By Clifton Ray

The stock of MyoKardia, Inc. (NASDAQ:MYOK) is a huge mover today! The stock increased 3.49% or $1.9 during the last trading session, reaching $56.3. About 235,205 shares traded. MyoKardia, Inc. (NASDAQ:MYOK) has risen 11.16% since February 18, 2017 and is uptrending. It has underperformed by 5.54% the S&P500.
The move comes after 5 months positive chart setup for the $2.01 billion company. It was reported on Feb, 18 by We have $61.37 PT which if reached, will make NASDAQ:MYOK worth $181.08M more.

Analysts await MyoKardia, Inc. (NASDAQ:MYOK) to report earnings on March, 12. They expect $-0.40 EPS, down 190.91 % or $0.84 from last year’s $0.44 per share. After $-0.42 actual EPS reported by MyoKardia, Inc. for the previous quarter, Wall Street now forecasts -4.76 % EPS growth.

MyoKardia, Inc. (NASDAQ:MYOK) Ratings Coverage

Among 5 analysts covering MyoKardia (NASDAQ:MYOK), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. MyoKardia had 5 analyst reports since November 23, 2015 according to SRatingsIntel. BMO Capital Markets initiated MyoKardia, Inc. (NASDAQ:MYOK) on Wednesday, July 20 with “Outperform” rating. The stock of MyoKardia, Inc. (NASDAQ:MYOK) has “Outperform” rating given on Monday, November 23 by Credit Suisse. Wedbush initiated MyoKardia, Inc. (NASDAQ:MYOK) rating on Monday, November 23. Wedbush has “Outperform” rating and $22 target. Cowen & Co initiated MyoKardia, Inc. (NASDAQ:MYOK) on Monday, November 23 with “Outperform” rating. The stock has “Outperform” rating by Wells Fargo on Friday, December 4.

More recent MyoKardia, Inc. (NASDAQ:MYOK) news were published by: which released: “MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in …” on February 14, 2018. Also published the news titled: “MyoKardia Announces Appointment of Cynthia Ladd as General Counsel” on January 19, 2018.‘s news article titled: “MyoKardia Provides Update on MYK-491 Clinical Progress” with publication date: September 27, 2017 was also an interesting one.

MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. The company has market cap of $2.01 billion. The Company’s lead product candidate is MYK-461, an orally-administered small molecule that is in Phase II clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy . It currently has negative earnings. The firm also develops MYK-491, an orally-administered small molecule that treats genetic dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: